Senior Director, Nonclinical, Clinical & Quantitative Pharmacology
Alexion, AstraZeneca Rare Disease
Dr. Chandra Udata is currently a Senior Director, Nonclinical, Clinical and Quantitative Pharmacology at Alexion, AstraZeneca Rare Disease at their Boston, MA, USA site. He has over 20 years pharmaceutical industry experience in the discovery, development and approval of small and large molecules, including antibody-drug conjugates (ADCs) and CAR-T cells with a focus on quantitative clinical pharmacology, PK/PD, drug metabolism, and translational sciences. He joined Alexion in 2020 from Pfizer where he worked for ~20 years and led a small group in early oncology clinical pharmacology group. During his 20+ years tenure at Alexion and Pfizer/Wyeth, he held varying levels of seniority starting out as a research scientist/individual contributor on project teams, senior scientist, pharmacology sub team cross functional leader, clinical pharmacology group leader and Senior Director. He had published/presented over 50 manuscripts in various journals and meetings. He received his B. Pharm (hons.) from the Birla Institute of Technology and Science, Pilani, India and Ph.D. in Pharmaceutical Sciences & Pharmacology from the University of Missouri-Kansas City. He has been a member of ASCPT since 2010 and has served on biologics committee.
Disclosure information not submitted.
Wednesday, January 12, 2022
3:30 PM – 4:30 PM ET
.png)